Algernon Pharmaceuticals Inc
OTCQB:AGNPFView on Canadian Exchange

  • LAST PRICE
    0.0572
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    ---/ ---
  • Ask / Lots
    ---/ ---
  • Open / Previous Close
    --- / 0.0572
  • Day Range
    ---
  • 52 Week Range
    0.0353
    0.1230
  • Volume
    ---

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Nov 4, 2024

      Show headlines and story abstract

    • 6:30PM ET on Monday Nov 04, 2024 by Dow Jones
      Companies Mentioned: AGN

      Algernon Announces Warrant Extension

      THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES

      VANCOUVER, British Columbia, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the "Company" or "Algernon") a Canadian clinical stage pharmaceutical development company announces that it has extended the expiry date of an aggregate of 4,752,969 outstanding warrants (the "2023 Warrants"). The 2023 Warrants were issued in connection with the closing of a rights offering by the Company on May 5, 2023.

Peers Headlines

No documents available